TABLE 1.
Overview of a selection of activating and inhibitory NK cell receptors in humans and/or mice and their corresponding ligandsa
| Receptor type | Human |
Mouse |
||
|---|---|---|---|---|
| Receptor | Ligand(s) | Receptor | Ligand(s) | |
| Activating | DNAM-1 (CD226) | PVR (Necl5, CD155), nectin 2 (CD112) | DNAM-1 (CD226) | PVR (Necl5, CD155), nectin 2 (CD112) |
| CRTAM (CD355) | Necl-2 | CRTAM (CD355) | Necl-2 | |
| NKG2D | MICA/B, ULBP1 to -6 | NKG2D | Rae-1, MULT-1, H60 | |
| NKp46 (CD335) | Viral HA, and HN, CFP (properdin) | NKp46 | Viral HA, CFP (properdin) | |
| NKp44 (CD336) | Viral HA and HN, PCNA,b MLL5, PDGF-DD | |||
| NKp30 (CD337) | B7-H6, BAT3, HCMV pp65c | |||
| CD16 | Fc portions of IgG | CD16 | Fc portions of IgG | |
| 2B4 (CD244) | CD48 | 2B4 (CD244) | CD48 | |
| Activating KIR | HLA-A11,-Bw4, -C(Asn77-Lys80) | |||
| NKp80 | AICL1 | |||
| NKp65 | KACL | |||
| CD94-NKG2C/E/H | HLA-E (for CD94-NKG2C) | KLRD1-KLRC2/3 (CD94-NKG2C/E) | Qa-1(b) | |
| PILR beta | CD99 | |||
| Tactile (CD96) | CD155 (Necl5, CD155) | Tactile (CD96) | PVR (Necl5, CD155), nectin 1 (CD111) | |
| Inhibitory | Inhibitory KIR | MHC class I polymorphisms | Inhibitory Ly49 | MHC class I |
| NKR-P1A | LLT1 | |||
| NKR-P1B | Clr-b | |||
| CD94-NKG2A/B | HLA-E | KLRD1-KLRC1 (CD94-NKG2A) | Qa-1(b) | |
| TIGIT | PVR (Necl5, CD155), nectin 2 (CD112) | TIGIT | PVR (Necl5, CD155), nectin 2 (CD112) | |
| LIR-1 (ILT-2/CD85j/LILRB1) | HLA (α3), HCMV UL18 | |||
| IRp60 (CD300a) | PS, PE | CD300a | PS, PE | |
| CEACAM1 (CD66) | CEACAM1 (CD66), TIM-3 (HAVCR2) | CEACAM1 | CEACAM1, TIM-3 (HAVCR2) | |
Abbreviations: DNAM-1, DNAX accessory molecule 1; PVR, poliovirus receptor; Necl, nectin-like molecules; CRTAM, class I-restricted T cell-associated molecule; MHC, major histocompatibility complex; MIC, MHC class I chain-related protein; ULBP, UL16 binding proteins; Rae-1, retinoic acid early inducible 1; MULT-1, mouse UL-16-binding protein-like transcript 1; H60, minor histocompatibility protein 60; HCMV, human cytomegalovirus; BAT3, human leukocyte antigen (HLA)-B-associated transcript 3; AICL, activation-induced C-type lectin; KACL, keratinocyte-associated C-type lectin; PILR, paired immunoglobulin-like type 2 receptor; KIR, killer-cell immunoglobulin-like receptor; CRTAM, class I-restricted T cell-associated molecule; HA, hemagglutinin; HN, hemagglutinin-neuraminidase; IgG, immunoglobulin G; LLT1, lectin-like transcript 1; TIGIT,T cell immunoglobulin and immunoreceptor tyrosine-based activation motif (ITIM) domain; PS, phosphatidylserine; PE, phosphatidylethanolamine; CEACAM, carcinoembryonic antigen-related cell adhesion molecules; CFP, complement factor P; PDGF, platelet-derived growth factor; IRp60, inhibitory receptor protein 60; TIM-3, T cell immunoglobulin domain and mucin domain 3; PCNA, proliferating cell nuclear antigen; MLL5, mixed lineage leukemia 5; LIR-1, leukocyte immunoglobulin-like receptor 1; HAVCR2, hepatitis A virus cellular receptor 2; LILRB1, leukocyte immunoglobulin-like receptor, subfamily B member 1; ILT-2, immunoglobulin-like transcript 2.
Triggers inhibitory signaling via NKp44.
Interferes with the activating signaling of NKp30.